PMID- 33591930
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1943-2704 (Electronic)
IS  - 1044-7946 (Linking)
VI  - 33
IP  - 2
DP  - 2021 Feb
TI  - Cryopreserved Placental Membranes Containing Viable Cells Result in High Closure 
      Rate of Nonhealing Upper and Lower Extremity Wounds of Non-Diabetic and 
      Non-Venous Pathophysiology.
PG  - 34-40
AB  - INTRODUCTION: Higher closure rates for chronic diabetic foot ulcers (DFUs) and 
      venous leg ulcers (VLUs) have been reported for placental products adjunct to 
      standard of care (SOC) vs SOC alone; however, data for other types of wounds are 
      limited. OBJECTIVE: This study aimed to evaluate the clinical outcomes of 
      amnion-derived and chorion-derived cryopreserved placental membranes containing 
      viable cells (vCPM) in the treatment of nonhealing upper-extremity and 
      lower-extremity wounds of nondiabetic and nonvenous pathophysiology. The authors 
      hypothesized that treatment with vCPM adjunct to SOC would result in positive 
      clinical outcomes for these wounds. MATERIALS AND METHODS: Data for all patients 
      consecutively treated between January 2016 and May 2019 with vCPM adjunct to SOC 
      were retrospectively collected and analyzed through chart review at a single 
      center. Patients with wounds of diabetic and venous pathophysiology and patients 
      receiving other skin substitutes during the course of vCPM treatment were 
      excluded from the study. Outcomes included wound closure, time to closure, number 
      of applications, and vCPM-related adverse events (AEs). RESULTS: Ninety-two 
      patients with 104 wounds received vCPM applications adjunct to SOC. The median 
      wound size was 3.15 cm2 (mean, 12.7 cm2) with a median duration of 1.5 months 
      (mean, 3.9 months). Eighty-seven of the 104 wounds (83.7%) achieved complete 
      wound closure in a median time of 41 days and 3 applications of vCPM. There were 
      no differences in closure rates between upper-extremity and lower-extremity 
      wounds, nor between the amnion and chorion products. There were no vCPM-related 
      adverse events. CONCLUSIONS: This study provides valuable information to 
      physicians, hospitals, and payers as it pertains to medically necessary and 
      appropriate patient treatment.
FAU - Johnson, Eric L
AU  - Johnson EL
AD  - Bozeman Health Deaconess Hospital, Wound and Hyperbaric Center, Bozeman, MT.
FAU - Saunders, Molly
AU  - Saunders M
AD  - Osiris Therapeutics, Columbia, MD.
FAU - Thote, Tanushree
AU  - Thote T
AD  - Osiris Therapeutics, Columbia, MD.
FAU - Danilkovitch, Alla
AU  - Danilkovitch A
AD  - Osiris Therapeutics, Columbia, MD.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Wounds
JT  - Wounds : a compendium of clinical research and practice
JID - 9010276
SB  - IM
MH  - *Diabetic Foot/therapy
MH  - Female
MH  - Humans
MH  - Lower Extremity
MH  - *Placenta
MH  - Pregnancy
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Wound Healing
EDAT- 2021/02/17 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/02/16 17:10
PHST- 2021/02/16 17:10 [entrez]
PHST- 2021/02/17 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PST - ppublish
SO  - Wounds. 2021 Feb;33(2):34-40.